Related Experiment Video
Updated: Feb 8, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus
Emily Clayton1,2, Moushimi Amaya3, Dung Nguyen1,2
1Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Abstract:
Nipah virus and Hendra virus are highly pathogenic henipaviruses for which there are no approved therapeutics for use in humans. Using recombinant Cedar virus expressing luciferase (rCedV-Luc) as a CL2 surrogate, we screened a library of 2,703 Food and Drug Administration (FDA)-approved compounds, yielding 5 promising candidates: bortezomib, harringtonine, homoharringtonine, ixazomib citrate and lanatoside C. Compounds demonstrated low half-maximal inhibitory concentration (IC50) values of ≤0.45 µM and high selectivity indexes >6 in mammalian cell lines. Time-of-addition studies suggest that these compounds target a post-entry stage of henipavirus replication. This study demonstrates the utility of rCedV-Luc as a surrogate for the antiviral screening of henipaviruses and identification of promising candidates for further investigation and development as henipavirus antivirals.
More Related Videos
10:29The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Published on: November 12, 2010
09:07Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
What are Viruses?
Viral Recombination
Introduction to Virus
Viruses of Archaea
Recombinant DNA